Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.37 |
| ▸ | TK2 | O00142 | 8/20 | 0.37 |
| ▸ | TK1 | P04183 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8744222 | 0.87 | TK2 (0.41) | TK2TK1 | |
| SCHEMBL9396543 | 0.84 | RNASE1 (0.39) | RNASE1TK2TK1 | |
| SCHEMBL4949384 | 0.84 | TK2 (0.39) | RNASE1TK2TK1 | |
| SCHEMBL8583926 | 0.83 | DNMT1 (0.30) | — | |
| SCHEMBL27561054 | 0.81 | TK1 (0.43) | TK2TK1 | |
| SCHEMBL28238519 | 0.78 | TK1 (0.40) | TK2TK1 | |
| SCHEMBL8145394 | 0.78 | TK1 (0.42) | TK2TK1 | |
| SCHEMBL20379162 | 0.76 | TYMP (0.41) | TK2TK1 | |
| SCHEMBL5163085 | 0.75 | TK2 (0.43) | TK2TK1 | |
| SCHEMBL7192452 | 0.75 | TK2 (0.35) | TK2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093990-A1 | Nucleotide with an Alpha-Phosphate Mimetic | ROCHE DIAGNOSTICS GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| EP-2147010-A1 | NUCLEOTIDE WITH AN ALPHA-PHOSPHATE MIMETIC | Roche Diagnostics GmbH (DE) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008128686-A1 | NUCLEOTIDE WITH AN ALPHA-PHOSPHATE MIMETIC | ROCHE DIAGNOSTICS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-1994022883-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDES AND THEIR PREPARATION | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022886-A1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022454-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT OXYGEN AND NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093990-A1 | Nucleotide with an Alpha-Phosphate Mimetic | PNP, APRT, PPA1 | RNASE1 787/4885TK2 125/4885TK1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.